JP2017516104A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516104A5
JP2017516104A5 JP2016567654A JP2016567654A JP2017516104A5 JP 2017516104 A5 JP2017516104 A5 JP 2017516104A5 JP 2016567654 A JP2016567654 A JP 2016567654A JP 2016567654 A JP2016567654 A JP 2016567654A JP 2017516104 A5 JP2017516104 A5 JP 2017516104A5
Authority
JP
Japan
Prior art keywords
mass spectrometry
amount
norendoxifene
tamoxifen
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567654A
Other languages
English (en)
Japanese (ja)
Other versions
JP6279104B2 (ja
JP2017516104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030419 external-priority patent/WO2015175561A1/en
Publication of JP2017516104A publication Critical patent/JP2017516104A/ja
Publication of JP2017516104A5 publication Critical patent/JP2017516104A5/ja
Application granted granted Critical
Publication of JP6279104B2 publication Critical patent/JP6279104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567654A 2014-05-12 2015-05-12 質量分析によるタモキシフェンおよびその代謝産物の定量化 Active JP6279104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992214P 2014-05-12 2014-05-12
US61/992,214 2014-05-12
PCT/US2015/030419 WO2015175561A1 (en) 2014-05-12 2015-05-12 Quantitation of tamoxifen and metabolites thereof by mass spectrometry

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018004851A Division JP6821610B2 (ja) 2014-05-12 2018-01-16 質量分析によるタモキシフェンおよびその代謝産物の定量化

Publications (3)

Publication Number Publication Date
JP2017516104A JP2017516104A (ja) 2017-06-15
JP2017516104A5 true JP2017516104A5 (enExample) 2017-07-27
JP6279104B2 JP6279104B2 (ja) 2018-02-14

Family

ID=54367635

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016567654A Active JP6279104B2 (ja) 2014-05-12 2015-05-12 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2018004851A Active JP6821610B2 (ja) 2014-05-12 2018-01-16 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2021000689A Pending JP2021073450A (ja) 2014-05-12 2021-01-06 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2023080724A Pending JP2023109874A (ja) 2014-05-12 2023-05-16 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2025018885A Pending JP2025081382A (ja) 2014-05-12 2025-02-07 質量分析によるタモキシフェンおよびその代謝産物の定量化

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018004851A Active JP6821610B2 (ja) 2014-05-12 2018-01-16 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2021000689A Pending JP2021073450A (ja) 2014-05-12 2021-01-06 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2023080724A Pending JP2023109874A (ja) 2014-05-12 2023-05-16 質量分析によるタモキシフェンおよびその代謝産物の定量化
JP2025018885A Pending JP2025081382A (ja) 2014-05-12 2025-02-07 質量分析によるタモキシフェンおよびその代謝産物の定量化

Country Status (9)

Country Link
US (6) US9459267B2 (enExample)
EP (2) EP3143392B1 (enExample)
JP (5) JP6279104B2 (enExample)
CN (2) CN110044998B (enExample)
AU (6) AU2015259294A1 (enExample)
BR (1) BR112016026459B1 (enExample)
CA (1) CA2948823C (enExample)
SA (1) SA516380291B1 (enExample)
WO (1) WO2015175561A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384437B1 (en) * 2008-12-24 2018-12-12 Quest Diagnostics Investments Incorporated Mass spectrometry assay for pregnenolone and 17-hydroxypregnenolone
AU2015259294A1 (en) 2014-05-12 2016-12-01 Quest Diagnostics Investments Llc Quantitation of tamoxifen and metabolites thereof by mass spectrometry
CN105159539B (zh) * 2015-09-10 2018-06-01 京东方科技集团股份有限公司 可穿戴设备的触控响应方法、装置及可穿戴设备
CA3153535A1 (en) 2019-10-10 2021-04-15 Rachel MULLEN Liquid chromatography-mass spectrometry (lc-ms) methods for analyzing ampholyte lot variation
JP2023512075A (ja) 2020-01-31 2023-03-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド オリゴヌクレオチドを特徴解析するための液体クロマトグラフィーおよび質量分析の使用
US12105102B2 (en) 2022-03-30 2024-10-01 University Of Utah Research Foundation Methods for quantifying insulin-like growth factor-1 and insulin-like growth factor-2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
IES950928A2 (en) * 1995-12-08 1996-02-21 Bunskellig Limited "A process for analysing a fluid"
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
AU2463299A (en) 1998-01-23 1999-08-09 Analytica Of Branford, Inc. Mass spectrometry from surfaces
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7485623B2 (en) * 2002-12-18 2009-02-03 Laboratoires Besins International Sa Reduction of breast density with 4-hydroxy tamoxifen
NZ542499A (en) 2003-04-01 2008-10-31 Besins Int Lab Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE472102T1 (de) * 2003-12-26 2010-07-15 Takeda Pharmaceutical Verfahren zur vorhersage von anomalien des lipidmetabolismus
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US8017403B2 (en) * 2007-06-14 2011-09-13 Quest Diagnostics Investments Incorporated Mass spectrometry method for measuring vitamin B6 in body fluid
US20090134325A1 (en) * 2007-11-27 2009-05-28 Goldman Mildred M Methods for detecting estradiol by mass spectrometry
US8916385B2 (en) * 2007-12-13 2014-12-23 Quest Diagnostics Investments, Inc. Methods for detecting estrone by mass spectrometry
US7834313B2 (en) 2008-08-08 2010-11-16 Quest Diagnostics Investments Incorporated Mass spectrometry assay for plasma-renin
JP2012517238A (ja) * 2009-02-11 2012-08-02 カリス エムピーアイ インコーポレイテッド 腫瘍の分子プロファイリング法
JP5953232B2 (ja) * 2009-10-06 2016-07-20 ウィスコンシン・アルムニ・リサーチ・ファウンデーションWisconsin Alumni Research Foundation 薬物誘導性の心毒性の代謝バイオマーカー
WO2012119010A2 (en) * 2011-03-01 2012-09-07 Indiana University Research And Technology Corporation Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
WO2012167126A1 (en) * 2011-06-03 2012-12-06 Purdue Research Foundation Ion generation using modified wetted porous materials
CN104203961B (zh) * 2012-03-05 2017-05-17 泽维尔大学 作为用于治疗乳腺癌的基于硼的4‑羟基他莫昔芬和因多昔芬前药
WO2014014279A1 (ko) * 2012-07-17 2014-01-23 서울대학교 산학협력단 질량 스펙트럼의 재현성 향상 방법 및 이를 이용한 정량 분석 방법
CN103494787B (zh) * 2013-07-22 2014-10-29 南通广泰生化制品有限公司 枸橼酸他莫昔芬滴丸
AU2015259294A1 (en) * 2014-05-12 2016-12-01 Quest Diagnostics Investments Llc Quantitation of tamoxifen and metabolites thereof by mass spectrometry

Similar Documents

Publication Publication Date Title
JP2017516104A5 (enExample)
JP2018077253A5 (enExample)
Berg et al. 13C labelled internal standards—A solution to minimize ion suppression effects in liquid chromatography–tandem mass spectrometry analyses of drugs in biological samples?
Qi et al. Derivatization for liquid chromatography-mass spectrometry
Helm et al. Ion mobility tandem mass spectrometry enhances performance of bottom-up proteomics
MX2017015229A (es) Metodos para la cuantificacion espectrometrica de masas de analitos extraidos de un dispositivo de micromuestreo.
JP2011530701A5 (enExample)
Wu et al. Simultaneous determination of amantadine, rimantadine and memantine in chicken muscle using multi-walled carbon nanotubes as a reversed-dispersive solid phase extraction sorbent
WO2015184321A3 (en) Rare molecule detection
WO2012092281A3 (en) Quantitation of insulin by mass spectrometry
Zhang et al. Simultaneous determination of 12 illicit drugs in whole blood and urine by solid phase extraction and UPLC–MS/MS
JP2011505013A5 (enExample)
JP2019503493A5 (enExample)
JP2011504596A5 (enExample)
SA516380291B1 (ar) الحساب الكمي لتاموكسيفين ونواتج أيضه بواسطة القياس الطيفي الكتلي
WO2013184995A8 (en) Methods and apparatus for performing mass spectrometry
Wong et al. Advances in rapid detection of SARS-CoV-2 by mass spectrometry
Kailasa et al. Electrospray ionization tandem mass spectrometry for rapid, sensitive and direct detection of melamine in dairy products
JP2021067524A5 (enExample)
JIANG et al. Application of Q-Orbitrap high resolution mass spectrometry to the detection of illegal adulterated antihyperlipidemics in herbal medicines and dietary supplements
MX379918B (es) Metodos para analisis y resolucion de preparaciones de dianhidrogalactitol y derivados o analogos del mismo.
RU2018104707A (ru) ИСПОЛЬЗОВАНИЕ МОЛЕКУЛЯРНЫХ МАРКЕРОВ IL-3, IL-33 и IL12ρ40 ДЛЯ ХАРАКТЕРИСТИКИ СТЕПЕНИ ТЯЖЕСТИ РЕСПИРАТОРНЫХ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ ЧЕЛОВЕКА И МЕТАПНЕВМОВИРУСОМ ЧЕЛОВЕКА
RU2015104248A (ru) Способ идентификации органических соединений методом хроматр-масс-спектрометрии
MX2023006071A (es) Metodo y aparato para la ionizacion quimica de muestras.
Rincón et al. Evaluation of peripheral blood microsampling techniques in combination with liquid chromatography‐high resolution mass spectrometry for the determination of drug pharmacokinetics in clinical studies